cancer panel

Respondents to a 2013 survey described changes in the way hereditary breast and ovarian cancer risk is assessed, interpreted, and conveyed to patients following the court decision.

Thermo is launching a program to develop its NGS Oncomine products into companion diagnostics, with the University Hospital Basel as its first partner.

Gencurix aims to achieve US FDA 510(k) clearance for its GenesWell BCT breast cancer prognostic test next year.

Groups from Austria, Spain, Germany, and the US demonstrated that the GeneReader can reliably detect cancer mutations in tissue and liquid biopsy samples.

Such analyses can help researchers pinpoint how various cancers evolve and determine the best kinds of tests to use to find certain disease information.

In a conference call to discuss the firm's fourth-quarter and full-year earnings, senior management highlighted recent developments and outlined expectations for 2017.

The activity follows a recent financing round that has enabled OncoDNA to build out its sales team as it courts new clients.

OncoDNA has launched two new precision cancer medicine projects, the budgets for which total €16 million and are being supported in part by the Belgian Walloon Region.

The team will use the new research grant to further develop the Stockholm3 prostate cancer test and to design follow-on diagnostics to help treat patients with the disease.

Based on the results, the researchers, based in Toronto, have initiated a clinical study in Ontario, called OCTANE, that involves a number of cancer centers in the province.

Pages

A fire at a Manchester hospital may have destroyed lab equipment and data, the Guardian reports.

Researchers generate a genetic database from skeletal remains from the 1845 Franklin Expedition to the Arctic, Live Science reports.

Researchers in China have begun another trial using CRISPR/Cas9 approaches in cancer patients, according to the Wall Street Journal.

In Science this week: human DNA found in sediments from archeological sites lacking bones, and more.